153) ages for IL-23 secretion to promote colon tumor progression. |
154) d find that NSD2 loss strongly attenuates tumor progression. |
155) aphics and characteristics of the primary tumor and BM. |
156) treatment in placental site trophoblastic tumor and epithelioid trophoblastic tumor |
157) and the rare placental site trophoblastic tumor and epithelioid trophoblastic tumor |
158) Surgical excision of the tumor and hydrocephalus treatment is usual |
159) Rapidly proliferating tumor and immune cells need metabolic prog |
160) Mathematical modeling, in which a tumor and its microenvironment are conside |
161) ) demonstrated a significant reduction in tumor and lung metastasize sizes without s |
162) oliferation and invasion in vitro, and on tumor and metastasis development in vivo. |
163) racterized by at least one sebaceous skin tumor and one visceral malignancy. |
164) LDH activity produces L-2HG in pancreatic tumor and stromal cells, modulating tumor |
165) convolution methods developed to separate tumor and stromal signatures can be applie |
166) genesis of keloid from the perspective of tumor and summarizes the tumor characteris |
167) neous flap after operation, recurrence of tumor, and the appearance and texture of f |
168) that several SG components play a role in tumorigenesis and cancer metastasis via tu |
169) epithelium is a rare, benign intraocular tumor. |
170) ) is the most aggressive and deadly brain tumor. |
171) all-molecule agent to be delivered to the tumor. |
172) hibit the recurrence and proliferation of tumor. |
173) nd most common type of intracranial brain tumor. |
174) ed the mutation profile of the respective tumor. |
175) ding neutrophil trafficking to the breast tumor. |
176) Ovarian cancer (OC) is a highly malignant tumor. |
177) bstance, which excluded the recurrence of tumor. |
178) ffer by sex or anatomical location of the tumor. |
179) oaches to understanding this recalcitrant tumor. |
180) n lung cancer tissues and the matched non-tumor tissues were determined by using qPC |
181) S100A7 were remarkably upregulated in 341 tumor tissues (P < .001) and 274 serum |
182) that lncRNA PANTR1 was upregulated in HCC tumor tissues and abundantly expressed in |
183) ard more specific therapeutic delivery in tumor tissues and cells. |
184) ould prolong the residence time of DOX in tumor tissues and promote the endocytosis |
185) ted the mechanism of CuET accumulation in tumor tissues by employing MDA-MB-231 huma |
|